In other news, GSK recently agreed to a nonexclusive material transfer, patent and know-how license deal with the Health Protection Agency (HPA) for the development and manufacture of a next-generation polio vaccine...The agreement allows the HPA to contribute to global polio eradication, while securing a commitment from a major pharma firm to develop use of its technology

To date, 150 patients out of a total of 200 patients have already been recruited in 16 centers in Germany, Austria and Israel...Lallemand Pharma, of Lugano Switzerland, partnered with Cipla Ltd., of Mumbai, India, to market and distribute PMBL tablets in India, under the name Pulmigen, for prevention of chronic bronchopulmonary infections...ProBioGen AG, of Berlin, said another undisclosed global pharma company licensed rights to its GlymaxX ADCC-enhancement technology

At all doses tested, ALX-0061 was well tolerated and the safety profile compared favorably to data reported for other biological DMARDs...In both studies the JE vaccine was shown to be highly immunogenic in children/adolescents age 2 months to younger than 18 years with a safety profile comparable to pediatric vaccines licensed for other diseases

Pursuant to the terms, each of the company's ordinary shares, including shares represented by American depositary shares (ADS), will be cancelled in exchange for the right to receive $2.20 in each per share, or $15.40 per ADS...Due to the oversubscription, the closing unit price was set at NIS3.544 per unit

to test AXL1717, an oral small-molecule insulin-like growth factor 1 receptor inhibitor, in patients with malignant astrocytomas, a type of brain tumor...In other news, Novartis said the FDA approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia

Toxicity experiments conducted to date revealed best-in-class potential with a greatly improved therapeutic index compared to other armed antibodies, due to an impressive safety profile, according to the company, which has opened a manufacturing facility in Nijmegen for the production of ADCs up to Phase III trials and early launches

In other news, Evotec said it expanded its collaboration with MedImmune, part of London-based AstraZeneca plc, after hitting a key milestone...Under the agreement, Pepscan will use its CLIPS platform and other protein mimicry technologies to help discover new antibodies

BioAlliance Pharma SA, of Paris, said the European Independent Board of Experts held its first meeting on the ReLive Phase III trial evaluating the efficacy of Livatag (doxorubicin Transdrug) in primary liver cancer and recommended continuing the global, multicenter, randomized study without modification...The application is for a pediatric label extension, based on Phase III studies showing the vaccine to be highly immunogenic in children between 2 months and 18 years, with a favorable safety

Distribution of Prothena ordinary shares in the demerger is conditioned upon, among other conditions to the demerger, a registration statement filed with the SEC, having been declared effective by the SEC and the affirmative vote of the Elan shareholders...Galderma Pharma SA, of Lausanne, Switzerland, and Valeant Pharmaceuticals International Inc., of Montreal, reached agreement on terms of a revised North American aesthetics arrangement, resolving Galderma's pending litigation related to Valeant's

In other news, Orexo said the FDA accepted for review its new drug application for Zubsolv, a sublingual formulation of buprenorphine and naloxone, and set a PDUFA date of July l6, 2013...Tiltan Pharma Ltd., of Jerusalem, said it enrolled the first U.S

Ironwood plans to initiate Phase I studies in healthy volunteers to assess the pharmacokinetics of IW-2143...CellAct Pharma GmbH, of Dortmund, Germany, said its topoisomerase inhibitor CAP7.1 showed promising safety and tolerability in heavily pretreated solid tumors...Immune Pharmaceuticals Ltd., of Herzlyia-Pituach, Israel, and EpiCept Corp., of Tarrytown, N.Y., entered a merger agreement, anticipated to close in the first quarter of 2013, that will create a combined company – Immune Pharmaceuticals

In other news, Cellectis said it signed two exclusive license agreements with Iowa State University granting the firm worldwide rights to inventions related to TAL effector-nucleases (TALENs) and monomeric TALENs...Pharma Two B Ltd., of Rehovot, Israel, completed a second round of financing for $8 million to develop its fixed-dose-combination product, P2B001, for Parkinson's disease and to complete a Phase IIb trial

Acceleron Pharma Inc., of Cambridge, Mass., reported preclinical data demonstrating positive effects of ACE-536, a modified Type II activin receptor fusion protein, to treat both the severe anemia and serious organ damage due to iron overload in a model of beta-thalassemia...The FDA requested studies to explore the safety profile of Oxycyte because perfluorocarbon emulsions as a class have been shown to cause transient thrombocytopenia in animals and humans, and have raised questions regarding

An oral oxazolidinone antibiotic targeting infections due to multidrug-resistant Gram-positive bacteria, MRX-I is designed to have enhanced potency against methicillin-resistant Staphylococcus aureus and an improved safety profile compared to marketed antibiotics

The agreement follows promising results from early stage trials showing the vaccine candidate had an acceptable safety profile and demonstrated an immune response...Versant will provide equity financing to the company, and Roche will fund the research based on a series of milestones...Roche retains an exclusive option to acquire Inception 3 upon a first lead compound reaching the filing stage of an investigational new drug application

The Phase IIb is designed to identify the patient population, defined by biomarker or other disease characteristic, for advancement into the Phase III portion of the trial...Biomarker findings and other patient selection and treatment experience from the Phase IIb stage will be incorporated into the design of Phase III, which the company plans to discuss with the FDA before launching the study this year, Farmer said...The two have nothing to do with each other

In other news, BioLineRx said BL-7010, an oral candidate in celiac disease and gluten sensitivity, was found to be safe and well tolerated in preclinical studies presented at the Better Life for Coeliacs 2012 Conference in Helsinki, Finland...Moberg Derma AB, of Stockholm, Sweden, said it completed recruitment of 97 patients with actinic keratosis on the head or face for the ongoing Phase II study of Limtop, a formulation of imiquimod designed for shorter treatment duration, improved safety profile

In other news, Almirall and Quintiles Transnational Corp., of Durham, N.C., entered a long-term strategic partnership to promote Almirall's respiratory portfolio in the UK, strengthening the companies' existing relationship...In other news, Eisai published results from a pivotal Phase III study (Study 304) of Fycompa (perampanel), for partial-onset seizures, in subjects 12 and older showing that once-daily perampanel 8 mg or 12 mg improved seizure control, and that both doses were safe and well

In other news, Boehringer said findings from an analysis of four Phase III trials, comparing Pradaxa (dabigitran etexilate) to enoxaparin recently published in Thrombosis Research, supported the positive safety profile of Pradaxa for the prevention of venous thromboembolism in patients undergoing total knee or hip arthroplasty